Highlights from ADA 85th Scientific Sessions

Highlight Videos

American Diabetes Association (ADA) Scientific Sessions

ADA Scientific Sessions - 2026

ADA Scientific Sessions - 2025

ADA Scientific Sessions - 2024

European Association for the Study of Diabetes (EASD) Annual Meeting

EASD Annual Meeting - 2025

Highlights from American Diabetes Association (ADA) 85th Scientific Sessions

Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, IL, USA, taking place 20-23 June 2025!

Supported by an unrestricted educational grant from Lilly and Novo Nordisk.

Click on the tabs below to watch videos from the ADA 85th Scientific Sessions.

Ramzi Ajjan

Over-the-Counter Continuous Glucose Monitoring – Data for All or a Disaster Waiting to Happen?

Ramzi Ajjan

If You Had to Pick Just One – GLP-1RA, GIP/GLP-1RA or SGLT2i for Type 2 Diabetes?

Roger Chen

When the Treatment of Type 2 Diabetes Becomes Nuanced

Roger Chen

Bridging the Gap – The Brain-Peripheral Nervous System Connection in Diabetes

Sof Andrikopoulos

Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists – Can They Become Players?

Sof Andrikopoulos

Diabetes and Peripheral Artery Disease – Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial

Tania Markovic

Why Are We Still Recommending Low-Fat Dairy?

Mark Cooper

Efficacy and Safety of CagriSema in Adults with Overweight/Obesity – The REDEFINE 1 and REDEFINE 2 Clinical Trials

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

Thomas Kay

Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy

Christopher Nolan

New Perspectives on Fetal and Placental Responses to Diabetes and Its Treatment

Alex Viardot

Do GLP-1/GIP-RAs Worsen or Improve Mental Health and Suicidality?

Jonathan Shaw

Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide

Jonathan Shaw

Diabetes and Peripheral Artery Disease – Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial

Sarah Glastras

Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide

So-Hun Kim

Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide

Tamara Milder

Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide

Elif Ekinci

Results from REGENT-1, an Open-Label, Prospective Study in Type 2 Diabetes

Angela Lee

The Role of CGM in Staging Early Type 1 Diabetes

Sarah Glastras

Glucometabolic Outcomes in Patients with Concurrent Overweight/Obesity and Type 1 Diabetes following Prolonged GLP-1 RA Treatment – A Systematic Review and Meta-analysis

Joanna Gong

Edwin Bierman Award Lecture – Diabetes and Cardiovascular Disease – An Evolving Story with Multiple Dimensions

Jihye Heo

SOUL Rationale, Design, and Baseline Characteristics

So-Hun Kim

First Report of a Phase 3 RCT of Orforglipron, a Small Nonpeptide GLP-1RA, as Monotherapy in Drug-Naïve Type 2 Diabetes with Inadequate Glycemic Control – The ACHIEVE-1 Trial

Yong-Ho Lee

Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes – A 52-Week Phase 2 Study

Hung-Yuan Li

Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists – Can They Become Players?

Samuel Chen

5 Take-Aways from ADA 2025

Yau-Jiunn Lee

Highlights from ADA 2025

Horng-Yih Ou

Controversies in Continuous Glucose Monitoring

Yong-Ho Lee

Metabolic and Molecular Characteristics of MASH

Lee-Ling Lim

Lancet Journal Symposium – Early-Onset Type 2 Diabetes

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.